ClinicalTrials.gg
CompletedNCT00393328Updated Apr 8, 2011

Bioequivalence Study of Atazanavir 300 mg Capsule

A Phase 1 interventional study of Atazanavir + Ritonavir and Atazanavir + Ritonavir in HIV Infections, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-04-08.

Sponsored by Bristol-Myers Squibb · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing atazanavir in HIV Infections — none open to participants now, 1 under way, 1 of them phase 3. atazanavir · HIV Infections.

Enrollment
42nd of 69
46 · median 55
Started
2006
with 11 others
Phase 1
16 of 73
none open now
Registered
38th of 73
by date
Lead sponsor
25 of 73
Bristol-Myers Squibb

Among the 73 studies testing atazanavir in HIV Infections, this one is the 42nd largest by enrollment of the 69 interventional ones that give a count, is one of 12 that started in 2006, is one of 16 in phase 1, and was the 38th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 73 studies testing atazanavir in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About atazanavir

atazanavir: first FDA approval 2003 (REYATAZ), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 73 studies testing atazanavir in HIV Infections as a file.
02

Study summary

The purpose of this clinical research study is to assess the bioequivalence of atazanavir administered as a single 300 mg capsule relative to two atazanavir 150 mg capsules in healthy subjects.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy male and female subjects between the ages of 18 to 50 years old with a (BMI) of 18 to 30 kg/m²
  • Prior to enrollment, subjects must have physical and laboratory test findings within normal limits, and women of (WOCBP) must have a negative pregnancy test.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
46 participants

Study arms

  • Active comparator
    A

    Drug: Atazanavir + Ritonavir

  • Active comparator
    B

    Drug: Atazanavir + Ritonavir

Interventions

  • DrugAtazanavir + Ritonavir

    Drug pages: Atazanavir · Ritonavir

    Capsules, Oral, ATV 300mg as 2-150mg + RTV 100mg, single dose, 7 days washout crossed over to Treatment B.

    Also known as: Abilify

  • DrugAtazanavir + Ritonavir

    Drug pages: Atazanavir · Ritonavir

    Capsules, Oral, ATV 300mg as single cap + RTV 100mg, single dose, 7 days washout.

    Also known as: Abilify

06

What researchers measure

Primary outcomes

  1. Blood atazanavir pharmacokinetic sampling to be collected on days 1, 2 and 3 of each of the 2 periods of the study

Secondary outcomes

  1. Blood ritonavir pharmacokinetic sampling to be collected on days 1, 2 and 3 of each of the 2 periods of the study

  2. Safety parameters including physical exam (PE), vital signs (VS), electrocardiogram (ECG) and clinical laboratory tests will be collected at study discharge

07

Study locations

1 site
  • Local Institution
    Hamilton, New Jersey, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2006
First posted
Oct 27, 2006
Start
Nov 2006
Primary completionActual
Dec 2006
CompletionActual
Dec 2006
Last update
Apr 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00393328
First posted
Oct 27, 2006
Start date
Nov 2006
Primary completion
Dec 2006
Completion
Dec 2006
Last update
Apr 8, 2011

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atazanavir · Ritonavir

Start the discussion